A phase 2 trial of botensilimab and balstilimab in colorectal cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy is a phase 2, randomised interventional study registered as NCT07227636 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 284 participants, started 2025-11-07 and due to reach its primary completion in 2030-11. Interventions recorded: Botensilimab; Balstilimab; Placebo. Conditions listed: Colorectal Cancer; Rectal Cancer. Primary outcome: Rate of ctDNA clearance (Cohort 1a); Rate of ctDNA clearance (Cohort 1b); Recurrence-free survival (RFS) (Cohort 2a). Colorectal eligibility wording from the registry: "* Histologically- or cytologically- confirmed colorectal cancer". Sites: United States. No results are recorded here; the registry entry is the source.
Shares Agenus, Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Agenus, Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Agenus, Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot) and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares Botensilimab, Balstilimab, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.
Shares MRD / molecular residual disease testing, Colorectal cancer trials open today (registry snapshot), Rectal cancer and the tag colorectal-deep-dive.